Hansa Biopharma AB
20
3
4
11
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
25.0%
5 terminated/withdrawn out of 20 trials
68.8%
-17.8% vs industry average
20%
4 trials in Phase 3/4
91%
10 of 11 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (20)
Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohorts
Role: lead
Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Tx
Role: lead
A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Group
Role: lead
Imlifidase Prior to Kidney Transplant in Highly Sensitised Children
Role: lead
A Study With Imlifidase in Anti-GBM Disease
Role: lead
A Gene Transfer Therapy Study to Evaluate the Safety and Efficacy of Delandistrogene Moxeparvovec (SRP-9001) Following Imlifidase Infusion in Participants With Duchenne Muscular Dystrophy (DMD) Determined to Have Pre-existing Antibodies to Recombinant Adeno-Associated Virus Serotype (rAAVrh74)
Role: collaborator
Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
Role: lead
A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantation
Role: lead
An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMR
Role: lead
A Study of Imlifidase in Patients With Guillain-Barré Syndrome
Role: lead
A Follow up Study of Patients Treated With Imlifidase Prior to Kidney Transplantation
Role: lead
Efficacy and Safety of GNT0003 Following Imlifidase Pre-treatment in Severe Crigler-Najjar Syndrome
Role: collaborator
An Efficacy and Safety Study of Imlifidase in Treatment of Antibody-Mediated Rejection in Kidney Transplant Patients
Role: lead
Ides in Highly Sensitized (HS) Patients Awaiting Kidney Transplantation
Role: collaborator
Open-Label Phase II Study to Evaluate the Efficacy and Safety of IdeS in Anti-GBM Disease
Role: collaborator
A Phase II Study to Evaluate the Efficacy of IdeS to Desensitize Transplant Patients With a Positive Crossmatch Test
Role: lead
IdeS in Asymptomatic Antibody-Mediated Thrombotic Thrombocytopenic Purpura (TTP) Patients
Role: lead
Study to Evaluate the Safety, Tolerability, Efficacy and PK of IdeS in Kidney Transplantation
Role: lead
Phase II Study, Evaluation of Safety and Efficacy of IdeS in Chronic Kidney Disease
Role: lead
Safety Study on IdeS in Healthy Volounteers
Role: lead
All 20 trials loaded